pharmaceuticals

Global Positive Allosteric Modulator Market

April 4, 2022
ID: SR/PH-06
Format:Pdf
Pages:220

Global Positive Allosteric Modulator Market by Disease Type (Parkinson’s disease, Schizophrenia, Alzheimer’s disease, Others), By Drug Type (Galantamine, Benzodiazepines, Barbiturates, Amantadine, Donepezil, Levodopa, Others), By End-User (Hospital, Pharmacy, Others), and By Region (North America, Europe, Asia-Pacific, Latin America, and The Middle East & Africa)-Global Forecast to 2028

Description

Positive Allosteric Modulator Market Overview

The global Positive Allosteric Modulator market was valued at USD 1,651.5 million in 2021 and is projected to hit around USD 2,911.3 million by 2028, expected to grow at a compound annual growth rate (CAGR) of 8.3% from 2022 to 2028. Allosteric modulators bind to a receptor and change their response to a stimulus. Positive allosteric modulators aid Agonist-mediated responses. Positive allosteric modulators are employed as a unique therapy strategy for patients with mental diseases such as dementia, schizophrenia, and others, estimated to drive the global market. Patients can be given positive allosteric modulators in combination with their existing approved anti-AD medicines to boost the efficacy of the drugs. In addition, the market is expected to expand primarily due to the rising number of cases of Alzheimer’s disease.

Furthermore, according to the World Health Organization (WHO), 55 million people worldwide will have dementia by 2020, with approximately 10 million new cases per year. Alzheimer’s disease accounts for 60-70% of these cases. Moreover, allosteric modulators are used in medical research and drug development. According to World Bank data, healthcare expenditures accounted for 9.78% in 2018, while research and development expenditures accounted for 2.1%.

What is Positive Allosteric Modulator?

Positive allosteric modulators increase agonist affinity or efficacy. A substance’s affinity is its ability to bind to a receptor, while effectiveness is its ability to activate a receptor. The chemical is classified as an antagonist if its effectiveness is zero. GABAA receptor positive allosteric modulators are PAM compounds that increase the activity of the GABAA receptor protein in the central nervous system of vertebrates. GABAA receptor PAMs provide sedative and anxiolytic effects when used as medicines.

Growth Drivers

Rising Anxiety Disorders cases

According to the World Health Organization, the estimated number of persons living with anxiety disorders worldwide was 264 million in 2015, up 14.9% from the previous year. The growing elderly population reduced side effects, increased efficacy of new/innovative medications, and the rising frequency of anxiety and depression disorders are all driving this industry forward. Anxiety was a major sector of the worldwide allosteric modulator market in 2017 and is likely to remain so during the forecast period. The increase in demand for anxiety treatments and growth in the number of businesses investing in new anxiety drugs drove the market revenue.

Increasing Need for better and Effective Treatment Outcomes

Concerns about non-adherence to oral schizophrenia medication and the consequent return of symptoms are predicted to be other significant factors driving the global schizophrenia treatment market expansion. As a result, a type of schizophrenia treatment known as long-acting injectables has gained popularity (Los). The long-acting injectable (LAls) version is used in several important and recent medication approvals for schizophrenia. Based on these trends, several major market players are concentrating their efforts on developing this type of schizophrenia medication. Long-acting injectables have several advantages, including preventing patient non-adherence to medications and extending the medication’s presence in the body.

Furthermore, the most important component of the long-acting injectable is that by preventing non-adherence, these schizophrenia medicines can successfully minimize the number of relapses, leading to cognitive and irreversible brain damage. The market is expected to increase rapidly during the projected period due to these long-acting injectables and their high efficacies.

Pre Covid-19 Impact on Global Positive Allosteric Modulator Market

Before pandemic, Companies are enhancing their product offerings and launching new products in response to advancements in diagnostic technologies and ongoing research activities in the field, which, when combined with other business expansion initiatives such as mergers and acquisitions, strategic collaboration, and new investments into other companies, are expected to complement the market’s growth over the forecast period.

Covid-19 Impact on Global Positive Allosteric Modulator Market

The COVID-19 pandemic has been transforming the growth of numerous markets, and the outbreak’s immediate impact is varied. While demand in a few industries has decreased, countless other areas may continue to thrive and offer potential growth prospects. Initially, the global COVID-19 outbreak and the lockdown scenario in several countries created some obstacles for the market, owing to hospitals and clinics’ refusal to provide services.

Post Covid-19 Impact on Global Positive Allosteric Modulator Market

Because the COVID-19 pandemic has disrupted the pharmaceutical supply chain, many items sold in various nations, such as the United States, Europe, and other countries, were affected by pharmaceutical manufacturing and export restrictions. Some pharmaceuticals are created in-house by pharmaceutical businesses, while others are manufactured in other countries, such as contract manufacturing services, which has impacted the product supply chain. As a result, the market expansion has been hampered by the delayed supply of second-generation antipsychotics in pharmacies and other end-user settings due to restrictions or cancellations on pharmaceutical export.

By Disease type

Based on the disease type, the market is categorized as Parkinson’s disease, Schizophrenia, Alzheimer’s disease, Others. The Parkinson’s disease segment is expected to hold a significant share of the global Positive Allosteric Modulator market over the forecast period. Parkinson’s disease is a neurodegenerative disease that primarily affects the areas of the brain responsible for movement control, making daily activities challenging. Parkinson’s disease is characterized by tremors, stiffness, trouble walking, and other symptoms caused by a decline in dopamine production. Many pharmaceutical companies are pursuing research to discover novel Parkinson’s disease therapies, creating strategic research cooperation. This will benefit market revenue as a result of this element. For instance, in October 2018, Pfizer Inc., a well-known pharmaceutical company, partnered with Bain Capital to launch Cerevel Therapeutics, a biopharmaceutical company focused on developing drugs for Parkinson’s disease and other central nervous systems disorders, boosting the Parkinson’s ricpAcp drugs market further.

By Drug type

The market is classified Galantamine, Benzodiazepines, Barbiturates, Amantadine, Donepezil, Levodopa, Others. The Benzodiazepines segment is estimated to have a significant share of the global Positive Allosteric Modulator market over the forecasted period by 2028. Anxiety, sleeplessness, panic disorder, seizures, and alcohol withdrawal are all treated with benzodiazepines, a class of psychotropic medicines. By boosting the impact of the neurotransmitter GABA, benzodiazepine medications generate a calming effect (Gamma-Aminobutyric Acid). Benzodiazepines are extensively prescribed medications around the world, and they can aid with anxiety disorders, seizures, sleep induction, and sedation before surgery or general anesthesia. An increase in the senior population, a hectic lifestyle, and everyday routines contribute to mental disturbances like anxiety, mania, and panic disorder. Due to an increase in the prevalence of anxiety, seizures, sleeplessness, and a surge in concern for avoiding stress and related diseases, the market for benzodiazepine medications is fast growing.

By Region Segment Analysis

Based on region segment, the market is bifurcated into North America, Europe, Asia-Pacific, South America, and The Middle East & Africa. North America is predicted to have the greatest market share over the projection period. Because of increasing health awareness among the population and easy access to quality healthcare in developed countries such as the United States, the market in North America is expected to obtain the biggest market share throughout the forecast period. Furthermore, the region’s increased investment in R&D activities is likely to enhance the market growth.

Competitors Analysis

The Companies Acadia Pharmaceuticals Inc., Eli Lilly and Company, Novartis AG, Sanofi-aventis Groupe, Bayer AG, Abbott Laboratories, Johnson & Johnson Services, Inc., Siemens Healthcare GmbH, Merck & Co., Inc., Pfizer Inc., and Other Prominent Players in the Positive Allosteric Modulator Market.

Key Stakeholders

Market research and consulting firms
Industry Associations
Local Governments
Regulatory bodies
Positive Allosteric Modulator Market providers
Suppliers
Retailers
Service Providers

Recent Developments

In February 2022, Acadia Pharmaceuticals Inc. announced the FDA submission of a supplemental New Drug Application (sNDA) for Pimavanserin to treat hallucinations and delusions associated with Alzheimer’s disease psychosis.
In June 2020: Interim HealthCare Inc. launched a free dementia caregiver’s guide for home care for patients living with dementia or Alzheimer’s disease.

Scope of the Report

Report Attribute	Details
Market Size Value in 2021	USD 1,651.5 million
The revenue forecast in 2028	USD2,911.3 million
Growth Rate	CAGR of 8.3% from 2022 to 2028.
Historical data	2017 – 2020
Forecast period	2022 – 2028
Region covered	North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Key companies Profiled	The Companies Acadia Pharmaceuticals Inc., Eli Lilly and Company, Novartis AG, Sanofi-aventis Groupe, Bayer AG, Abbott Laboratories, Johnson & Johnson Services, Inc., Siemens Healthcare GmbH, Merck & Co., Inc., Pfizer Inc., and Other Prominent Players in the Positive Allosteric Modulator Market.

Market Modelling

By Disease Type

Parkinson’s disease
Schizophrenia
Alzheimer’s disease
Others

By Drug Type

Galantamine
Benzodiazepines
- Diazepam
- Clonazepam
- Lorazepam
- Lorazepam
Barbiturates
- Methohexital
- Phenobarbital
- Secobarbital
Amantadine
Donepezil
Levodopa
Others

By End-User

Hospital
Pharmacy
Others

By Region

North America
Europe
Asia-Pacific
South America
The Middle East & Africa

Table Of Contents

Methodology

Request Sample

Frequently Asked Questions (FAQ):

What is Positive Allosteric Modulator?

What is the growth rate of the global Positive Allosteric Modulator Market?

The global Positive Allosteric Modulator Market is valued at USD 1651.5 million in 2021 and is projected to hit around USD 2,911.3 million by 2028, expected to grow at a compound annual growth rate (CAGR) 8.3% from 2022 to 2028.

What are the growth elements of the global Positive Allosteric Modulator Market?

Patients can be given positive allosteric modulators in combination with their existing approved anti-AD medicines to boost the efficacy of the drugs. The market is expected to expand primarily due to the rising number of cases of Alzheimer’s disease.

Which region is expected to have the largest share in the global Positive Allosteric Modulator Market?

North America is expected to have the largest share in the global Positive Allosteric Modulator Market.

Who are the major players in the global Positive Allosteric Modulator Market?

Select License

We Accept

Analyst support

After evaluating your requirements and addressing your technical problems, the expert analyst will resolve your query directly.

Customer satisfaction

According to your needs, our expert team will assist you with the capabilities, services, and proper research needs to be required and customize the report accordingly.

Inimitable expertise

Our expert team will create unrivaled reviews to provide you with a deep understanding of the reports.

Assured quality

We have created a systematic way to determine standards and satisfy your expectations.

Instant delivery

Unlike others, we provide you a great deal of instant delivery in the form of PDF/PPT/Word Doc directly to your email address within 24 hours after receiving full payment.

Privacy policy

We understand the inkling of your privacy, we will never misuse your email address.

Custom research service

We are giving you an opportunity through which you can directly ask our expert analyst to customize an exclusive study of the report to serve your research needs.

Quality & accuracy

We provide you with the accurate quality of the customized study of an exclusive report according to your research need.

Data visualization

As the business world’s growing faster every day, we understand the value of data management. We will create the reports by keeping all the visual data sets and metrics in the charts.

Information security

We truly respect your privacy and promise to keep your personal and confidential information safe and secure.

Global Positive Allosteric Modulator Market

Positive Allosteric Modulator Market Overview

What is Positive Allosteric Modulator?

Growth Drivers

Rising Anxiety Disorders cases

Increasing Need for better and Effective Treatment Outcomes

Pre Covid-19 Impact on Global Positive Allosteric Modulator Market

Covid-19 Impact on Global Positive Allosteric Modulator Market

Post Covid-19 Impact on Global Positive Allosteric Modulator Market

By Disease type

By Drug type

By Region Segment Analysis

Competitors Analysis

Recent Developments

Scope of the Report

Market Modelling

Report Content

Frequently Asked Questions (FAQ):

Select License

We Accept

Latest Reports

Why Choose Us

Quick Links

Industries We Serve

Contact Info